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Abstract
CXCL12 (stromal cell-derived factor 1) is a unique biological
ligand for the chemokine receptor CXCR4. We previously
reported that treatment with a specific CXCR4 antagonist,
AMD3100, exerts a beneficial effect on the development of
collagen-induced arthritis (CIA) in the highly susceptible IFN-γ
receptor-deficient (IFN-γR KO) mouse. We concluded that
CXCL12 plays a central role in the pathogenesis of CIA in IFN-
γR KO mice by promoting delayed type hypersensitivity against
the auto-antigen and by interfering with chemotaxis of CXCR4+
cells to the inflamed joints. Here, we investigated whether
AMD3100 can likewise inhibit CIA in wild-type mice and
analysed the underlying mechanism. Parenteral treatment with
the drug at the time of onset of arthritis reduced disease
incidence and modestly inhibited severity in affected mice. This
beneficial effect was associated with reduced serum
concentrations of IL-6. AMD3100 did not affect anti-collagen
type II antibodies and, in contrast with its action in IFN-γR KO
mice, did not inhibit the delayed type hypersensitivity response
against collagen type II, suggesting that the beneficial effect
cannot be explained by inhibition of humoral or cellular
autoimmune responses. AMD3100 inhibited the in vitro
chemotactic effect of CXCL12 on splenocytes, as well as in vivo
leukocyte infiltration in CXCL12-containing subcutaneous air
pouches. We also demonstrate that, in addition to its effect on
cell infiltration, CXCL12 potentiates receptor activator of NF-κB
ligand-induced osteoclast differentiation from splenocytes and
increases the calcium phosphate-resorbing capacity of these
osteoclasts, both processes being potently counteracted by
AMD3100. Our observations indicate that CXCL12 acts as a
pro-inflammatory factor in the pathogenesis of autoimmune
arthritis by attracting inflammatory cells to joints and by
stimulating the differentiation and activation of osteoclasts.
Introduction
Among chemokines, CXCL12 (formerly stromal cell-derived
factor 1) is unique in that it binds to one single chemokine
receptor, CXCR4, which itself is recognized by no other chem-
okines [1-3]. CXCL12 is produced physiologically in various
tissues and its receptor CXCR4 is also expressed on various
haematopoietic and non-haematopoietic cells. By binding to
heparan sulphate proteoglycans, secreted CXCL12 can
adhere to certain cells such as bone marrow stromal cells.
Through this mechanism, CXCL12-CXCR4 interaction plays
an important role in homing of myeloid and lymphoid cells to
specific sites in bone marrow or secondary lymphoid organs.
CXCR4 also acts as an important co-receptor for HIV entry
into CD4+ human lymphocytes [4]. Like other members of the
chemokine family, CXCL12 may play a role in inflammatory dis-
eases. Specifically, there is increasing evidence that CXCL12
plays a crucial role in patients with rheumatoid arthritis (RA). In
RA patients, abnormally high concentrations of CXCL12 in
synovial fluid and overexpression of CXCL12 in synovial cells
have been found [5-8]. Moreover, CXCR4+ leukocytes inR1208
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R1209synovia were found to be significantly more abundant [7]. Evi-
dence also points to a role for CXCL12 in positioning
CXCR4+ T and B cells to distinct synovial microdomains as
well as in retaining these cells within the inflamed synovial tis-
sue [9]. CXCL12 induces migration of monocytes into human
arthritic synovium transplanted into severe combined immuno-
deficiency (SCID) mice [10]. In addition to exerting these
effects on cell migration, CXCL12 also induces angiogenesis
during RA development [8] and stimulates chondrocytes to
release matrix metalloprotease 3 (MMP3), a matrix-degrading
enzyme involved in cartilage destruction [5].
Availability of specific inhibitors of the CXCL12-CXCR4 inter-
action has allowed the demonstration of the involvement of
CXCL12 in experimental animal diseases. One such inhibitor
is the bicyclam drug AMD3100, originally discovered as an
anti-HIV compound and which specifically interacts with
CXCR4 [11,12]. We found that AMD3100 reduces the sever-
ity of collagen-induced arthritis (CIA) in mice, a model for RA
in man. The study was done on IFN-γ knock-out (IFN-γR KO)
DBA/1 mice, which are more susceptible to CIA than wild-type
mice [13]. Reduced severity of arthritis was associated with a
significant reduction in the delayed type of hypersensitivity
(DTH) response to the auto-antigen collagen type II (CII). The
majority of leukocytes harvested from inflamed joints of
arthritic IFN-γR KO mice were found to be CD11b+, and
AMD3100 was demonstrated to interfere with the chemotaxis
induced in vitro by CXCL12 on purified CD11b+ splenocytes.
We concluded that CXCL12 contributes to the pathogenesis
of CIA in these mutant mice by promoting DTH and by interfer-
ing with migration of CD11b+ cells into joint tissues.
A major difference in the pathogenesis of CIA between IFN-γR
KO and wild-type mice is the presence of more extensive
extramedullary myelopoiesis in IFN-γR KO mice, leading to an
expansion of CD11b+ cells that can act as DTH and arthri-
togenic effectors [14-16]. Thus, in IFN-γR KO mice, the bal-
ance between cellular (DTH) and humoral autoimmune
responses seems to be shifted towards DTH, and this bias
may in part explain the beneficial effects of AMD3100 in IFN-
γR KO mice. We have tested this hypothesis in the present
study. We investigated to what extent AMD3100 affects CIA
in wild-type mice and, if so, which mechanisms are involved.
We found that AMD3100 does inhibit the disease but that, in
contrast to IFN-γR KO mice, this was not associated with
reduction in DTH reactivity against CII. We show that, aside
from inhibiting chemotaxis in vitro, AMD3100 also inhibits the
CXCL12-elicited cell migration into subcutaneous air pouches
in vivo. In addition, we found CXCL12 to be able to enhance
receptor activator of NF-κB ligand (RANKL)-induced osteo-
clast differentiation from splenocytes and to increase osteo-
clast activity, two effects that were counteracted by
AMD3100.
Materials and methods
Induction of collagen-induced arthritis
Mice of the DBA/1 strain were bred in the Experimental Animal
Centre of the Katholieke Universiteit Leuven (Leuven, Bel-
gium). The experiments were performed in 8- to 12-week-old
male mice that were age-matched within each experiment.
CII from chicken sternal cartilage (Sigma-Aldrich Co., St Louis,
MO, USA) was dissolved at 2 mg/ml in PBS containing 0.1 M
acetic acid by stirring overnight at 6°C. The CII solution was
emulsified with an equal volume of complete Freund's adjuvant
(CFA; Difco Laboratories, Detroit, MI, USA) with added heat-
killed Mycobacterium butyricum (Difco), reaching a final
Mycobacterium content of 750 µg/ml emulsion. Mice were
injected intradermally with 100 µl emulsion at the base of the
tail on day 0.
Mice were examined daily for signs of arthritis. The disease
severity was recorded for each limb, as described in [17]:
score 0, normal; score 1, redness and/or swelling in one joint;
score 2, redness and/or swelling in more than one joint; score
3, redness and/or swelling in the entire paw; score 4, deform-
ity and/or ankylosis.
All animal experiments were approved by the local ethical com-
mittee (University of Leuven).
Treatment with AMD3100
AMD3100 was provided by AnorMED (Langley, British
Columbia, Canada). For the treatment with AMD3100, Alzet
osmotic minipumps model 2002 (DURECT corporation,
Cupertino, CA, USA) were subcutaneously implanted at the
dorsolateral part of the body. During the procedure, the mice
were anaesthetized with a solution of PBS containing 0.2% (v/
v) Rompun (Bayer, Brussels, Belgium) and 1% (v/v) Ketalar
(Parke-Davis, Zaventem, Belgium). The minipumps delivered
AMD3100 at a constant rate of 600 µg/day for 14 days.
Histology
Fore and hind limbs (ankles and interphalanges) were fixed in
10% formalin and decalcified with formic acid. Paraffin sec-
tions were haematoxylin stained. Severity of arthritis was eval-
uated blindly using three parameters: infiltration of mono- and
polymorphonuclear cells; hyperplasia of the synovium; and
bone destruction. Each parameter was scored on a scale from
0 to 3: score 0, absent; score 1, weak; score 2, moderate;
score 3, severe.
Serum anti-collagen type II ELISA
Individual sera were tested for the amount of anti-CII antibody
by ELISA, as described previously [17]. Briefly, ELISA plates
(Maxisorp, Nunc, Wiesenbaden, Germany) were coated over-
night with chicken CII (1µg/ml; 100 µl/well; Sigma-Aldrich Co,
St Louis, MO, USA) in coating buffer (50 mM Tris-HCL, pH
8.5; 0.154 mM NaCl) followed by a 2 h incubation with
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0.1% (w/v) casein). Serial twofold dilutions of the sera and the
standard were incubated overnight in assay buffer (50 mM
Tris-HCl; pH 7.4; 154 mM NaCl and 0.5% Tween-20). The
quantification of total IgG was done by ELISA making use of a
standard with known IgG concentration. For determination of
the IgG2a, IgG2b and IgG1 antibody concentrations, a stand-
ard of arbitrary U/ml was used (standard = 1,000 U/ml). Plates
were then incubated for 2 h with biotinylated rat antibody to
mouse total IgG, IgG2a, IgG2b or IgG1 (Zymed Laboratories,
San Francisco, CA, USA). Plates were washed and incubated
for 1 h with streptavidin-peroxidase. Finally, the substrate 3,3'-
5,5'-tetramethyl-benzidine (Sigma-Aldrich Co.) in reaction
buffer (100 mM sodium acetate/citric acid, pH 4.9) was
added. Reaction was stopped using 50 µl H2SO4 2 M and
absorbance was determined at 450 nm.
Delayed-type hypersensitivity experiments
For evaluation of DTH reactivity, CII/CFA-immunized mice
were subcutaneously injected with 10 µg of CII/20 µl PBS in
the right ear and with 20 µl PBS in the left ear. DTH response
was calculated as the percentage swelling (the difference
between the increase of thickness of the right and the left ear,
divided by the thickness of the ear before challenge, multiplied
by 100).
Assays for in vivo leukocyte migration and for in vitro 
chemotaxis
For the in vivo assay, mice were treated with AMD3100 or
PBS as described above. The assay was performed on the last
day of the treatment. Six days before, mice were subcutane-
ously injected at the dorsolateral site of the body with 2.5 ml
of sterile air, creating a subcutaneous air pouch. At day three
before the assay, injection with 2.5 ml sterile air was repeated
at the same location. The chemotactic assay was performed
by injecting 1 ml 0.9% (w/v) NaCl/CXCL12 2 µg or 0.9% (w/
v) NaCl alone into the air pouch (human CXCL12 was pro-
vided by Dr I Clark-Lewis, University of British Columbia, Van-
couver, BC, Canada). Two hours later, cells were washed out
of the air pouch by 2 ml PBS/FCS 2% (v/v) and cells were
immediately counted with a light microscope in the Burker
chamber.
In vitro chemotactic assays were performed at day 21 post
immunization. Spleens were isolated and passed through cell
strainers to obtain a single cell suspension. Erythrocytes were
removed by lysis with NH4Cl (0.83% (w/v) in 0.01 M Tris-HCl,
pH 7.2; two consecutive incubations of 5 and 3 min, 37°C).
Splenocytes of three mice were pooled and incubated with
AMD3100 at different concentrations in assay buffer (HBSS,
20 mM Hepes, 0.2% (w/v) BSA, pH 7.2). Transwell filter mem-
branes (5 µm pore; Costar, Boston, MA, USA) were placed in
the wells of a 24-well plate, each containing 600 µl buffer with
or without CXCL12 at a concentration of 100 ng/ml (human
CXCL12 was provided by Dr I Clark-Lewis). 106 cells were
loaded on each Transwell filter. The plate was then incubated
for 3.5 h at 37°C, whereupon the filter inserts were carefully
removed. The migrated cells were collected and counted in a
flow cytometer (FACScalibur; Becton Dickinson, San Jose,
CA, USA) as described [18-20]. The number of cells is repre-
sented as the number of counts registered during a two-
minute acquisition (number of cells/2 minutes).
Migrated cells were incubated with anti-CD16/CD32 Fc-
blocking antibodies (BD Biosciences Pharmingen, San Diego,
CA, USA) and washed with PBS. After washing, the cells were
stained for 30 minutes with anti-CD4-PE, anti-CD8-FITC, anti-
CD19-PE or anti-CD11b-FITC (BD Biosciences Pharmingen).
Cells were washed, fixed with 0.37% formaldehyde in PBS,
and analysed by a FACScalibur flow cytometer (Becton
Dickinson).
The chemotactic index was calculated as the number of
migrated cells obtained with 100 ng/ml CXCL12 divided by
the number of cells in the negative control without CXCL12.
Flow cytometric analysis of cells from joint cavities
Cells from joint cavities were obtained by inserting a 25-gauge
needle into the ankle joint. Cold PBS (800 µl) was injected
into the joint cavity. Fluid exiting spontaneously from the open-
ing was collected and was only used when it was found to
contain <5% of erythrocytes. Cells were washed and resus-
pended in cold PBS. Cells were incubated with anti-CD16/
anti-CD32 Fc-receptor-blocking antibodies (BD Biosciences
Pharmingen). After washing, the cells were stained for 30 min-
utes with anti-CD11b-FITC and anti-CXCR4-PE or isotype
control rat IgG2b (BD Biosciences Pharmingen). Cells were
washed, fixed with 0.37% formaldehyde in PBS, and analysed
by a FACScalibur flow cytometer (Becton Dickinson).
Polymerase chain reaction
Synovial tissues from the ankle joints were carefully isolated
under a stereomicroscope. Total RNA was extracted with Tri-
zol reagent (Invitrogen, Paisley, Scotland, UK), in accordance
with the manufacturer's instructions. cDNA was obtained by
reverse transcription with a commercially available kit (Thermo-
script; Invitrogen) with oligo(dT)20 as primer.
For PCR reactions we used a TaqMan® Assays-on-Demand™
Gene Expression Product from Applied Biosystems (Foster
City, CA, USA; assay ID Mm00445552_m1). Expression lev-
els of the gene were normalized for 18S RNA expression.
Cytokine detection in serum and cultured medium
Control-treated and AMD3100-treated mice were bled both
before and 6 h after intraperitoneal injection with 10 µg anti-
CD3. Sera were collected and pooled. This allowed us to
determine the concentrations of the following cytokines: IL-1β,
IL-2, IL-4, IL-6, IL-10, IL-12, tumour necrosis factor-α and IFN-
γ.
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tion and were passed through cell strainers to obtain a single
cell suspension. Erythrocytes were removed by lysis with
NH4Cl (0.83% (w/v) in 0.01 M Tris-HCl, pH 7.2; two consec-
utive incubations of 5 and 3 minutes, 37°C). Splenocytes of
the mice were pooled and cultured in a 96-well plate. 105 cells
were cultured in one well in Roswell Park Memorial Institute
(RPMI) medium alone, RPMI with mouse CXCL12 (0.1 µg/ml)
(PeproTech, London, UK), or RPMI with mouse CXCL12 and
AMD3100 (25 µg/ml). Supernatant was collected after 48 h.
Detection of cytokine concentrations in serum and cultured
medium was done with the Endogen SearchLight™ array
(Pierce Boston Technology, Woburn, MA, USA).
In vitro induction of osteoclast formation by splenocytes
Spleens were isolated on day 21 after immunization and were
passed through cell strainers to obtain a single cell suspen-
sion. Erythrocytes were removed by lysis with NH4Cl (0.83%
(w/v) in 0.01 M Tris-HCl, pH 7.2; two consecutive incubations
of 5 and 3 minutes, 37°C). Leukocytes from the blood were
obtained by lysis of red blood cells by two incubations (5 and
3 minutes at 37°C) with NH4Cl solution (0.083% (w/v) in 0.01
M Tris-HCl; pH 7.2). Remaining cells were washed two times
with ice-cold PBS.
Splenocytes were suspended in Minimal Essential Medium
alpha Medium (α-MEM) containing 10% (v/v) FCS (GIBCO,
Invitrogen corporation, Paisley, Scotland, UK). Cells (2.5 ×
105) in a total volume of 400 µl were seeded in chamber slides
(LAB-TEK Brand Products, Nalge Nunc International, Naper-
ville, IL, USA). Cells were incubated with macrophage colony
stimulating factor (M-CSF; 20 ng/ml) + CXCL12 (0.1 or 0.5
µg/ml; AnorMED), with M-CSF + RANKL (100 ng/ml) +
CXCL12 or with M-CSF + RANKL + CXCL12 + AMD3100
(25 µg/ml; AnorMED). M-CSF and RANKL were obtained
from R&D Systems Europe (Abingdon, UK). On day 4, super-
natants were removed and cultures were provided with fresh
media and stimuli. On day 7, media were removed and cells
were stained for the presence of tartrate-resistant acid phos-
phatase (TRAP) (described below).
Pit-forming assay
Splenocyte suspensions were obtained as described above
and resuspended in α-MEM containing 10% (v/v) FCS
(GIBCO, Invitrogen Corporation). 106 cells were cultured for
5 days with M-CSF (20 ng/ml) and RANKL (100 ng/ml), both
from R&D systems Europe, on transparent quartz slides
coated with a calcium phosphate film (BioCoat Osteologic
Discs; BD Biosciences Pharmingen). On day 6, media were
removed and replaced with media containing M-CSF, M-CSF
+ CXCL12 (0.5 µg/ml), M-CSF + CXCL12 + AMD3100 (25
µg/ml) or M-CSF + AMD3100. Another two days later, cells
were removed and resorption pits were quantified using a Leitz
DM RBE microscope equipped with a colour video camera
(Optronics Engineering, Goleta, CA, USA) and attached to a
computer-aided image analysing system (Bioquant, R&M Bio-
metrics, Nashville, TN, USA). Quantification and size determi-
nation of the pits was performed at a magnification of ×20 in
15 areas of constant size, positioned adjacent to one another
and spanning the whole quartz slide. In all slides, the minimum
threshold of a pit surface area was set to 50 µm2. Upon thresh-
olding, the number and square surface of plaques are deter-
mined automatically.
Results
Inhibition of collagen-induced arthritis by AMD3100 in 
DBA/1 wild-type mice
In a first experiment, DBA/1 mice were immunized with CII in
CFA. The symptoms of arthritis started to appear on day 27; 4
mice out of 22 showed redness and/or swelling in one of their
joints. On that day, mice were divided in two subgroups,
matched for incidence and average clinical score. In one
group, mice were implanted with osmotic minipumps releasing
AMD3100 at a constant rate of 600 µg/day. Mice in the other
group were implanted with pumps delivering PBS. From previ-
ous experience and according to the manufacturer's specifica-
tion sheet, the minipumps are known to be active for two
weeks. Mice were scored six times a week for symptoms of
arthritis. Cumulative incidence and mean scores of arthritis in
both groups during the experiment are shown in Fig. 1a,b. The
cumulative incidence of arthritis rapidly increased in the con-
trol mice, but remained stable in the AMD3100-treated ani-
mals (Fig. 1a). In fact, after initiation of treatment, 7 out of 10
mice in the PBS group developed arthritis within 3 days,
whereas in the AMD3100-treated group only a single mouse
out of 8 developed symptoms 13 days after initiation of the
treatment. Correspondingly, the mean arthritic group score
gradually increased in controls, but not in AMD3100-treated
animals (Fig. 1b). The beneficial effect of AMD3100 in CIA
was confirmed in two additional experiments. The data of the
three experiments are summarized in Table 1: during the treat-
ment, in total only 2 out of 20 AMD3100-treated mice devel-
oped signs of arthritis against 16 out of 22 controls.
Considering all arthritic mice, the average clinical score of
arthritic mice was lower in the treated mice, although the dif-
ference compared with that in the arthritic control mice was
not statistically significant. Thus, the significantly lower aver-
age scores reached in the AMD3100-treated group, when all
mice are considered, reflects mainly the lower incidence in this
group. In addition, evaluation of disease progression in each of
the individual mice having arthritis signs at the initiation of
treatment revealed lower percent increases in disease scores
in the AMD3100- than in the PBS-treated group (Fig. 1c), sug-
gesting that AMD3100 can also exert a beneficial effect on
evolving arthritis. These in vivo results show that AMD3100
treatment of CIA initiated at first appearance of symptoms is
effective against the development and progression of the
disease.
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treated mice
To ascertain that the protective effect of AMD3100 with
respect to the clinical symptoms of arthritis was also manifest
at the histological level, five mice from each group (Table 1,
experiment 1) were sacrificed for histological examination of
the joints. These mice were selected such that their mean clin-
ical scores corresponded to the average score of the entire
group.
Haematoxylin-stained sections showed that the absence of
redness and swelling in AMD3100-treated mice corre-
sponded with the absence of infiltration of immunocompetent
cells and tissue destruction (Fig. 1d). Histological examination
of joint sections of AMD3100-treated mice that did show clin-
ical symptoms of arthritis revealed a weak hyperplasia and infil-
tration of mono- and polymorphonuclear cells in the synovium
(Fig. 1e). Sections of arthritic PBS-treated mice showed a
moderate to severe infiltration, hyperplasia of the synovium
and bone destruction (Fig. 1f).
AMD3100 does not interfere with humoral or cellular 
responses to collagen type II
The pathogenesis of CIA is generally considered to depend on
both humoral and cellular immunity against CII. To see whether
inhibition of CIA by AMD3100 acts via modulation of either of
these, we measured specific anti-CII antibodies and DTH
reactivity against CII. These tests were performed on day 14
after implantation of minipumps.
Total anti-CII IgG was determined in sera of the mice that were
sacrificed for histological analysis. Titers of these antibodies in
AMD3100-treated mice were not different from those in PBS-
treated mice (Fig. 2a). The remainder of the sera were pooled
and analysed for IgG2a, IgG2b and IgG1 isotypes against CII.
IgG2a was below detection limit in both groups. We found no
Figure 1
Inhibition of collagen-induced arthritis in DBA/1 mice by treatment with AMD3100. Mice were immunized on day 0 with collagen type II in complete 
Freund's adjuvant and were observed for symptoms of arthritis. On day 27, when the first symptoms of arthritis appeared, the mice were divided into 
two groups in a way that a similar incidence and a similar average clinical score was reached in both groups. On this day, mice of one group were 
implanted with osmotic minipumps, delivering AMD3100 for two weeks at a constant rate of 600 µg/day. Mice of the other group were implanted 
with pumps containing PBS. The (a) cumulative incidence and (b) mean arthritic score ± standard error of the mean (SEM) for AMD3100-treated 
and control-treated mice are shown. Average group scores of arthritis were significantly different from day 30 onwards (p ≤ 0.05 on day 30; p ≤ 0.01 
from day 31 till the end of the experiment, Mann-Whitney U test). (c) Evaluation of disease progression in mice with established arthritis at initiation 
of treatment with AMD3100. Circles represent percentage increase in scores of arthritis for individual mice at the end of the treatment. Data show 
the results of three individual experiments (explained in more detail in the legend of Table 1). (d-f) Histological analysis of the joints. On the last day 
of treatment, five mice out of both groups with a mean score representing the average group score, were selected and sacrificed. Paraffin sections 
of the fore and hind limbs were haematoxylin stained and histological examination was performed. Representative pictures are shown. (d) Joint of an 
AMD3100-treated mouse without clinical symptoms showing normal histological appearance. (e) Joints of arthritic AMD3100-treated mice show a 
weak infiltration of mono- and polymorphonuclear cells and hyperplasia of the synovium. (f) Joint section of a PBS-treated mouse, showing moderate 
to severe infiltration of leukocytes, hyperplasia and bone destruction.
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two groups (Fig. 2b). Thus, the absence of clinical and histo-
logical symptoms of arthritis in the AMD3100-treated mice
appeared not to be associated with any decreased antibody
response against CII, nor with a switch between isotypes.
Cellular-immune responsiveness to CII was tested in mice that
were immunized with CII/CFA and that were implanted on day
7 with osmotic minipumps containing AMD3100 or PBS. DTH
testing was done on day 17 after immunization (i.e., day 10 of
the treatment) by injecting 10 µg of CII in the right, and vehicle
(PBS) in the left ear. Bars in Fig. 2c represent the percentages
of swelling of the CII-challenged ears, normalized to the swell-
ing of the PBS-challenged ears. No inhibition of the DTH
response to CII was observed in the AMD3100-treated group
indicating that AMD3100 did not interfere with the cellular
immune response to CII.
AMD3100 blocks CXCL12-elicited cell migration in vivo 
and chemotaxis in vitro
To see whether AMD3100 inhibits CIA by blocking CXCL12-
mediated tissue infiltration, we immunized a set of 16 mice
with CII/CFA. At the time of disease onset (day 27) they were
divided into two subgroups matched by average incidence
and clinical score. One group was implanted with osmotic
minipumps delivering AMD3100. In the control group, pumps
were filled with PBS. An air pouch assay was done on day 14
after minipump implantation (day 41). In both the AMD3100-
treated and the PBS-treated group, four of the mice received
an injection into the air pouch with CXCL12 (2 µg in 1 ml of
0.9% (w/v) NaCl), and four other mice received an injection
with 0.9% NaCl. Two hours after this challenge, cells were
washed out of the air pouch using 2 ml PBS containing 2% (v/
v) FCS.
Cell counts are shown in Fig. 3a. Mice implanted with PBS-
delivering osmotic minipumps and challenged with 0.9% NaCl
during the air pouch assay were considered as negative
controls. In this group, an average of 1.5 ± 0.2 × 106 cells per
mouse was obtained from the air pouch. Mice that carried
PBS-delivering osmotic pumps and were injected with
CXCL12 into the air pouch were considered as positive con-
trols. In this group, we harvested an average of 3.4 ± 0.3 × 106
cells per mouse. This indicates specific infiltration of cells into
the air pouch, in response to the chemokine CXCL12. Chal-
lenging mice with CXCL12 while they were treated with
AMD3100 reduced the number of harvested cells to that of
the negative control. The number of cells in the air pouch of
AMD3100-treated mice after challenge with 0.9% NaCl was
similar to that in the negative controls, indicating that the
AMD3100-treatment did not, as such, affect the number of
cells in the air pouch. Furthermore, flow cytometric analysis of
the spleen and the lymph nodes did not reveal effects of
AMD3100 on the number or proportions of CD4+, CD8+,
CD19+ and CD11b+ cells. Together these data led us to con-
clude that treatment with AMD3100 is able to block CXCL12-
elicited infiltration in vivo so as to prevent infiltration into
inflamed tissues.
In vitro chemotactic assays performed on splenocytes of
immunized mice allowed us to investigate the dose-dependent
inhibition of CXCL12-elicited chemotaxis by AMD3100 (Fig.
3b). The percentage of cells that migrated in response to
CXCL12 gradually decreased when the cells were pre-incu-
bated with increasing concentrations of AMD3100. The dose-
Table 1
Inhibition of the incidence and mean score of CIA by treatment with AMD3100
Experiment number Treatmenta Cumulative incidence (%) Score of arthritis (mean ± SEM)
Start of treatmentb End of treatmentc All miced Arthritic mice onlye
1 AMD3100 2/10 (20%) 3/10 (30%)f 1.4 ± 0.9f 4.7 ± 2.4
Control 2/12 (17%) 9/12 (75%) 5.2 ± 0.9 6.2 ± 0.6
2 AMD3100 1/7 (14%) 2/7 (29%) 0.9 ± 0.6f 3.0 ± 1.0
Control 2/7 (29%) 5/7 (71%) 2.4 ± 0.8 3.4 ± 0.7
3 AMD3100 2/8 (25%) 2/8 (25%)g 0.6 ± 0.5g 2.5 ± 1.5
Control 1/8 (13%) 7/8 (88%) 3.9 ± 1.4 4.3 ± 1.5
The table shows the results of three individual experiments. Male mice were immunized with collagen type II/complete Freund's adjuvant on day 0. 
aAt the day first symptoms appeared (day 27 in experiment 1 and 2, day 24 in experiment 3), mice were divided into two groups and were 
implanted with osmotic minipumps delivering AMD3100 at a constant rate of 600 µg/day or PBS in the control groups. Distribution of the mice 
between the two groups was done in a way that an equal incidence and a similar clinical score was reached in both groups. bArthritic incidence in 
both groups at the start of the treatment is shown. cAt the end of the treatment, there was a significant inhibition of the incidence in the AMD3100-
treated group compared to the control in experiments 1 and 3 (fp < 0.05 and gp < 0.01, respectively; binomial proportion test). dAt the end of the 
treatment, the mean arthritic scores calculated for all mice were significantly different between the AMD3100-treated and control groups for all the 
three experiments (fp < 0.05 for experiments 1 and 2; gp < 0.01 for experiment 3; Mann-Whitney U-test). eAt the end of the treatment, the mean 
arthritic scores calculated for mice with symptoms of arthritis were not significantly different between the AMD3100-treated and control groups. 
SEM, standard error of the mean.
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R1214dependent inhibition by AMD3100 was confirmed in three
additional experiments (pooled data are represented in Fig. 3c
as the mean percentage of inhibition of CXCL12-elicited
chemotaxis).
Flow cytometric analysis was performed after chemotaxis and
revealed that CD4+, CD8+, CD19+ and CD11b+ cells were all
attracted to CXCL12 with a chemotactic index of 2.5, 2.7, 6.9
and 3.4, respectively.
Figure 2
AMD3100 in wild-type mice does not interfere with the humoral or the cellular response
cellular response. At the end of the two week treatment (day 41), blood 
was collected from five mice out of each group. (a) Sera of individual 
mice were analyzed for total anti-CII IgG, using an absolute standard. 
Bars represent averages plus standard error of the mean of five mice. 
(b) Equal quantities of the sera were pooled for detection of anti-CII 
IgG2b and IgG1, using a standard in arbitrary U/ml; standard = 1,000 
U/ml. (c) Delayed type hypersensitivity reactivity against CII. Ten mice 
were immunized with CII/complete Freund's adjuvant and implanted 
with osmotic pumps containing AMD3100 or PBS on day 7. On day 17 
after immunization, five mice in each group were challenged with 10 µg 
of CII in the right ear and vehicle in the left. Delayed type hypersensitiv-
ity responses were measured as the percentage of ear swelling (i.e. 
100 × the difference between the increase of thickness of the right and 
the left ear, divided by the thickness of the ear before challenge) at the 
indicated times. Bars represent averages ± standard error of the mean 
for five mice.
Figure 3
AMD3100 blocks CXCL12-elicited chemotaxis in vivo and in vitro. (a) 
Sixteen mice were immunized with collagen type II (CII) in complete 
Freund's adjuvant on day 0 and treated with AMD3100 or PBS in a 
similar way as described in the legend of Fig. 1. In vivo treatment is 
indicated along the X-axis. On the last day of treatment, a chemotactic 
assay was performed as described in Materials and methods. On that 
day, mice were injected with 2 µg of CXCL12 in 1 ml 0.9% NaCl (+) or 
0.9% NaCl only (-) in a subcutaneous air pouch. Two hours after chem-
okine challenge, cells were washed out of the air pouch with 2 ml of 
PBS/FCS 2% and counted. Counts of the individual mice are shown 
(circles) and average ± standard error of the mean are indicated for 
each group (diamonds). (b,c) Dose-dependent inhibition by AMD3100 
of CXCL12-elicited chemotaxis on total splenocytes. On day 21 post 
immunization with CII in complete Freund's adjuvant, spleens of three 
mice were pooled and a splenocyte suspension was prepared. Cell 
samples were pre-incubated for 10 minutes with AMD3100 at the indi-
cated concentrations. Then, 5-µm filter inserts were loaded with 106 
cells and transferred to a 24-well plate containing 100 ng/ml human 
CXCL12 in 600µl of buffer per well. After 3.5 h of incubation, the mem-
brane inserts were removed and the cells in the wells were collected 
and counted by flow cytometry. The numbers of migrated cells of one 
representative experiment are shown in (b). (c) The experiment was 
confirmed by three additional experiments and the data of the experi-
ments were pooled and represented as the percentage inhibition ± 
standard error of the mean of CXCL12-elicited chemotaxis by the indi-
cated concentrations of AMD3100.
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R1215Expression of CXCL12 and presence of CXCR4+ cells in 
the arthritic joint
To collect further evidence for the hypothesis that AMD3100
protects mice from arthritis by blocking CXCL12-mediated
leukocyte mobilization, we ascertained that CXCL12-elicited
migration of immunocompetent cells to inflamed sites does
take place during CIA development. Numbers of CXCL12
mRNA copies were found to be elevated in synovial cells of the
inflamed joint, as evident from quantitative reverse transcrip-
tion (RT)-PCR (Fig. 4a). Among cells harvested by synovial lav-
age from the arthritic joint, an average of 15% stained double
positive for CXCR4 and CD11b, as investigated by flow
cytometry (Fig. 4b). These data were confirmed in an addi-
tional experiment. Taken together, these findings are indicative
of CXCL12-elicited recruitment of CXCR4+CD11b+ leuko-
cytes to the joints as a mechanism contributing to CIA
pathogenesis.
Influence of AMD3100 on cytokine production
We also considered the possibility that, in the course of CIA
pathogenesis, CXCL12 might stimulate or enhance produc-
tion of certain cytokines and that this might be a pathway by
which AMD3100 could exert its protective action. To test this
possibility, we looked at possible differences in the cytokine
profiles of PBS- and AMD3100-treated mice. Eight mice were
immunized with CII/CFA and treated on day 25 with
AMD3100 (four mice) or PBS (four mice), using the osmotic
minipumps. On day 35 post immunization (day 10 of the treat-
ment), mice were bled and serum levels of IL-1β, IL-2, IL-4, IL-
6, IL-10, IL-12, TNF-α and IFN-γ were determined by Search-
Light proteome array. Only IL-6, IL-10, IL-12 and IFN-γ were
detectable in the sera of mice. AMD3100 failed to change the
levels of IL-10, IL-12 and IFN-γ, although blood levels of IL-6
were decreased in AMD3100-treated mice, a finding that was
confirmed in additional experiments (data from these experi-
ments are shown in Fig. 5a). Decreased systemic production
of IL-6 in AMD3100-treated mice may be an indirect effect of
inhibition of CXCL12-mediated cell traffic, as this might
reduce formation of inflammatory tissue in joints and possibly
other sites in the CII/CFA-immunized mice. Alternatively, inhib-
ited IL-6 production might signify that CXCL12, aside from its
chemotactic activity, directly activates certain CII/CFA-
exposed leukocytes to produce this cytokine. To help distin-
guish between these two possibilities, we tested the ability of
CXCL12 to induce the production of IL-6 in splenocyte cul-
tures. Splenocytes of CII/CFA-immunized mice were cultured
in the absence or presence of CXCL12 (0.5 µg/ml), with or
without AMD3100 (25 µg/ml) (Fig. 5b). IL-6 was detectable in
the supernatants of unstimulated cultures. Stimulation with
CXCL12 or CXCL12 + AMD3100 did not alter the IL-6 pro-
duction in the cultures, suggesting that the decreased IL-6
blood concentrations in the AMD3100-treated arthritic mice
reflected an indirect, rather than a direct, CXCL12 action on
IL-6 production.
Figure 4
Presence of CXCL12 RNA and CXCR4+ cells in the arthritic joint. (a) 
Synovia of three collagen type II/complete Freund's adjuvant-immunized 
collagen-induced arthritic (CIA) mice and three naive mice were iso-
lated on day 35 after immunization and total RNA was purified. 
Reverse-transcription was performed and cDNA was subjected to 
quantitative PCR and normalized to the amount of 18S RNA. (b) Joints 
of three other collagen type II/complete Freund's adjuvant-immunized 
mice were washed at day 35 with PBS/FCS 2%. Cells that were har-
vested from the joint were stained for the presence of CD11b using flu-
orescein isothiocyanate (FITC)-labeled antibodies, and for CXCR4 
using phycoerythrin (PE)-labeled antibodies. (c) Control staining for 
CXCR4 using a PE-labeled rat IgG2b isotype control antibody. One 
representative experiment out of two is shown.
Figure 5
IL-6 levels in serum and in CXCL12-stimulated splenocyte culturesi l l t  lt r . (a) 
Eight mice were immunized with collagen type II/complete Freund's 
adjuvant (CIA) and implanted with osmotic minipumps delivering 
AMD3100 (four mice) at a constant rate of 600 µg/day or containing 
PBS (four mice). Blood was collected at day 10 of the treatment. Sera 
were pooled in each group and analysed for the presence of IL-6 (using 
a SearchLight Proteome array). Bars represent the average ± standard 
error of the mean of two independent experiments. (b) Splenocytes of 
three collagen type II/complete Freund's adjuvant-immunized mice were 
pooled and cultured in the absence of CXCL12, in the presence of 
CXCL12 (0.5 µg/ml) or in the presence of CXCL12 and AMD3100 (25 
µg/ml). Supernatant was analysed after 48 h for the presence of IL-6. 
Bars represent the average ± standard error of the mean of three inde-
pendent experiments.
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activation
Osteoclast precursor cells and in vitro differentiated mature
osteoclasts have been found to express CXCR4 [21-23], a
finding that was confirmed in our laboratory (data not shown).
To test the hypothesis that CXCL12 might facilitate osteoclast
differentiation, splenocyte suspensions were cultured in the
presence of M-CSF and RANKL, in the presence or absence
of CXCL12 and/or AMD3100. After 6 days, osteoclasts were
identified by staining for TRAP, a marker enzyme for osteo-
clasts. In cultures stimulated with M-CSF and RANKL,
osteoclast differentiation could be observed (Fig. 6a–c). Addi-
tion of CXCL12 at a concentration of 0.1 µg/ml did not influ-
ence the number of osteoclasts (Fig. 6a). At 0.5 µg/ml,
however, significantly higher numbers of osteoclasts were
observed (Fig. 6b,d). Interestingly, when both AMD3100 and
CXCL12 (in either concentration) were added, less differenti-
ated osteoclasts appeared than in control cultures receiving
only M-CSF and RANKL (Fig. 6a,b,e). Reduced differentiation
of osteoclasts was not associated with increased mortality of
splenocytes in these cultures (data not shown).
We also tested the effect of CXCL12 on the osteoclasts' abil-
ity to dissolve bone mineral. Splenocytes were cultured on
quartz substrates, coated with a calcium phosphate film. Cells
were stimulated with M-CSF + RANKL. After 6 days, multinu-
cleated giant cells could be seen by microscopical
examination, but resorption of the calcium phosphate film was
not yet visible. On that day, the supernatant fluid was replaced
with medium containing M-CSF alone, M-CSF + CXCL12 (0.5
µg/ml), M-CSF + CXCL12 + AMD3100 or M-CSF +
AMD3100. Two days later, osteoclast activity was quantified
as the ability to resorb the calcium phosphate film; 1 resorp-
tion pit is the area resorbed by 1 osteoclast, and the area of
the pit correlates with osteoclast activity. The mean area of the
resorption pits in the different conditions was calculated using
a bioquant image analysis system (the data are presented in
Fig. 7a and representative pictures of the resorbed areas on
the calcium phosphate film are shown in Fig. 7b–d). It can be
seen that CXCL12 significantly increased osteoclast activity,
as evident from an increase in the resorbed area. When
AMD3100 was added to the cultures with or without
CXCL12, the osteoclast activity decreased significantly to a
Figure 6
CXCL12 stimulates and AMD3100 inhibits osteoclast differentiation. Splenocytes of three collagen type II/complete Freund's adjuvant-immunized 
mice were isolated and pooled. (a,b) Splenocytes were cultured for 6 days in the cups of a chamberslide, in the presence of the indicated stimuli 
(macrophage colony-stimulating factor (M-CSF), 20 ng/ml; receptor activator of NF-κB ligand (RANKL), 100 ng/ml; CXCL12, 0.1 µg/ml in (a), 0.5 
µg/ml in (b); AMD3100, 25 µg/ml). After stimulation, cells were fixed and stained for the presence of tartrate-resistant acid phosphatase (TRAP). 
TRAP+ multinucleated (three or more nuclei) cells were counted within each cup. Bars represent averages ± standard error of the mean for four cul-
tures. The asterisk represents p < 0.05 compared with the hatched bar (Mann-Whitney U-test). Representative pictures for TRAP-stained cultures 
stimulated with (c) M-CSF and RANKL alone and with added (d) CXCL12 (0.5 µg/ml) or (e) CXCL12 and AMD3100.
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When the number of pits were counted and grouped accord-
ing to their size, it appeared that CXCL12 also increased the
number of pits, irrespective of their size, although resorption
pits with a large area (>5,000 µm2) were most affected by
CXCL12. In contrast, such large pits were barely detectable in
cultures that had been treated with AMD3100 (Table 2).
Because AMD3100 decreased osteoclast differentiation (Fig.
6) and activation (Fig. 7) to a level beneath that of cultures
where no exogenous CXCL12 was added, we verified
whether splenocytes spontaneously produced CXCL12. To
this end, splenocytes were cultured for 2 days without stimu-
lation and CXCL12 concentrations in the supernatant were
determined using the SearchLight proteome array. The mean
Figure 7
CXCL12 increases and AMD3100 inhibits osteoclast activity. Splenocytes of three collagen type II/complete Freund's adjuvant-immunized mice 
were isolated and pooled. Cell suspensions were cultured for 6 days on a quartz substrate coated with a calcium phosphate film in the presence of 
macrophage colony-stimulating factor (M-CSF, 20 ng/ml) and receptor activator of NF-κB ligand (RANKL, 100 ng/ml). At day 6 media were 
removed, cultures were provided with fresh media and stimulated as indicated (M-CSF, 20 ng/ml; CXCL12, 0.5 ng/ml; AMD3100, 25 µg/ml). Cells 
were removed from the quartz substrate after 2 days and resorption pits were visualized by light microscopy. The resorbed area was measured by a 
bioquant image analysis system. Bars represent the mean area resorbed by 1 osteoclast (average ± standard error of the mean), measured as the 
area of 1 resorption pit. The asterisk represents p < 0.001 compared with the M-CSF condition (Mann-Whitney U-test). Representative pictures of 
resorption pits are shown for the condition stimulated with (b) M-CSF, (c) M-CSF + CXCL12 and (d) M-CSF + CXCL12 + AMD3100. The data in 
this figure are representative for two independent experiments.
Table 2
CXCL12 increases and AMD3100 inhibits osteoclast activity
Number of pits with indicated resorption areaa
In vitro stimulationb 50–100 µm2 100–500 µm2 500–1,000 µm2 1,000–5,000 µm2 >5,000 µm2
Control 481 1,002 166 153 22
CXCL12 848 1,854 382 346 90
CXCL12 + AMD3100 598 1,143 193 164 5
AMD3100 580 1,008 171 140 6
aThe table shows the number of osteoclast resorption pits for five different surface intervals. bSplenocytes of collagen type II/complete Freund's 
adjuvant-immunized mice were cultured as described in the legend of Fig. 8, and the resorbed area was measured.
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splenocyte cultures was 85 ± 26 pg/ml.
Taken together, these data reveal a positive effect of CXCL12
on osteoclast differentiation and activity. Moreover, the inhibi-
tion of osteoclast differentiation and activation by the CXCR4
antagonist suggests an important role for endogenous
CXCL12 in both processes.
Discussion
We had already established that CXCL12 plays an important
role in the pathogenesis of murine CIA in the highly sensitive
IFN-γR KO mouse [13]. In particular, treatment with the spe-
cific CXCL12 inhibitor AMD3100 had been shown to afford
protection against CIA. Examination of the underlying
mechanism led to the conclusion that AMD3100 interfered
with CXCL12-mediated immigration of leukocytes in the joints,
but also reduced the systemic DTH against CII that, in IFN-γR
KO mice, is typically more pronounced than in wild-type mice.
Here, we demonstrate that AMD3100 reduced the incidence
and progression of CIA in IFN-γR-competent mice, in a similar
manner to that previously demonstrated in IFN-γR KO mice
[13]. Thus, irrespective of whether the IFN-γ system is defec-
tive or intact, CXCL12 is a key cytokine in the pathogenesis of
murine CIA.
Quantitative RT-PCR revealed an increased presence of
CXCL12 mRNA in the inflamed synovium in comparison with
normal synovium, and 15% of the cells that could be harvested
from inflamed joints were found to be CD11b+CXCR4+ dou-
ble positive. Splenocytes from mice subjected to the CIA
immunisation schedule were found to display in vitro chemo-
tactic responsiveness to CXCL12, an activity that was
blocked by adding AMD3100. The in vivo relevance of these
effects in mice immunized to develop CIA was examined with
a subcutaneous air pouch system. CXCL12 injected into air
pouches elicited immigration of leukocytes, an effect that was
similarly blocked by AMD3100. These observations make it
seem likely that in wild-type mice, as in IFN-γR-deficient ones,
effects on leukocyte traffic constitute an important mechanism
by which CXCL12 favours the pathogenesis of CIA.
In the case of IFN-γR KO mice, protection by AMD3100 treat-
ment was associated with reduced cellular immune respon-
siveness to CII, as evident from reduced DTH in footpad
swelling tests [13]. In wild-type mice, in contrast, AMD3100
did not affect DTH reactivity against CII. Basal DTH to CII
following CIA induction was less pronounced in wild-type than
in IFN-γR KO mice, however, and this in itself might account
for it not being further reduced by AMD3100. Of note, another
CXCL12-CXCR4 inhibitor, 4F-benzoyl-TN14003, has been
shown to inhibit DTH to sheep red blood cells in normal Balb/
c mice [24]. The difference in mouse strain and the use of a
different antigen may account for the discrepancy between
our findings. Failure of AMD3100 to affect anti-CII DTH reac-
tivity in our wild-type mice suggests that, under the
circumstances, cellular immunity to CII is perhaps not a key
element by which CXCL12 influences the pathogenesis of
CIA.
Formation of antibodies to CII was similarly not affected by
AMD3100 treatment. Thus, although CXCL12 is known to act
as a B cell growth factor [25], its possible action on humoral
immunity to CII cannot be considered as a mechanism by
which it acts as a disease-promoting factor in wild-type DBA/
1 mice.
We also considered the possibility that CXCL12 favours CIA
development by somehow affecting systemic cytokine produc-
tion. In wild-type DBA/1 mice immunized to develop CIA, we
found production of circulating IL-6, and levels of this cytokine,
were reduced in mice treated with AMD3100. IL-6 is a crucial
cytokine for CIA development because treatment with anti-
bodies against IL-6 inhibits disease development [15]. In RA
patients, serum IL-6 concentrations correlate with disease
activity and decrease after effective treatment with disease
modifying antirheumatic drugs. We wondered whether
CXCL12 could induce IL-6 production and if this could be
inhibited by AMD3100. If so, this would be an additional
mechanism for AMD3100 to inhibit CIA development. We
found, however, that IL-6 production was not increased in
CXCL12-stimulated splenocyte cultures compared to unstim-
ulated ones. This suggests that the lower levels of IL-6 in the
serum of AMD3100-treated mice probably reflects the
effectiveness of the CIA treatment, occurring for example by
inhibition of leukocyte infiltration in the joint.
Furthermore, we investigated the possibility that CXCL12 can
induce production of RANKL and thereby stimulate differenti-
ation and/or activation of osteoclasts. If real, these activities
might constitute part of the role of CXCL12 in CIA pathogen-
esis and might in part explain the protective effect of
AMD3100. In fact, we found CXCL12 to be unable to induce
RANKL or RANK expression and osteoclast differentiation in
plain splenocyte cultures. The chemokine did potentiate
induction of osteoclasts in cultures exposed to RANKL plus M-
CSF, however, although it should be noted that the chemokine
dose required to see this effect was in large excess of levels
normally seen in CXCL12 production systems. Addition of
AMD3100 to the system annihilated the CXCL12 effect but,
intriguingly, reduced osteoclast induction to a level lower than
that seen in cultures not exposed to CXCL12. A possible
explanation may be that cultures exposed to M-CSF plus
RANKL release endogenous CXCL12 at a level such that
osteoclast induction is near to maximal, requiring supra high
doses of exogenous CXCL12 for further augmentation.
Grassi et al. [26] reported that CXCL12 can enhance bone
resorbing activity of osteoclasts. We similarly found that stim-
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phosphate-resorbing capacity. Moreover, addition of
AMD3100 to osteoclast cultures reduced their resorbing
potential. This inhibitory effect took place even if no exogenous
CXCL12 had been added, showing that the osteoclast-acti-
vating activity of CXCL12 operates at concentrations within
the endogenous physiological range.
Conclusion
As evident from our observations, we demonstrate that
CXCL12 plays a crucial role in the CIA pathogenesis of fully
IFN-γR-competent mice, as it was proven to be before in IFN-
γR KO mice. The underlying mechanisms are diverse,
however, and their relative impact may differ depending on
whether the IFN-γ system is defective or intact. In both cases,
effects on leukocyte migration to the inflamed joints seem to
play an important role. An enhancing effect of CXCL12 on cel-
lular immunity may play an additional important role in IFN-γR
KO mice, which are considerably more sensitive to the dis-
ease; this mechanism seems to be of less importance in wild-
type mice. Furthermore, we were able to document a potenti-
ating effect of CXCL12 on osteoclast differentiation and acti-
vation, both of which were counteracted by AMD3100. These
observations hold further promise for potential treatment of RA
patients with CXCR4 antagonists.
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